

5-31-05

Tfca

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/696,717
	Filing Date	October 29, 2003
	First Named Inventor	Wylie Vale
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	AO-CLFR:194USD1

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard 18 References
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	FULBRIGHT & JAWORSKI L.L.P.		
Signature			
Printed name	Melissa W. Acosta		
Date	May 27, 2005	Reg. No.	45,872

Transmittal

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 671534225 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: May 27, 2005

Signature: (Annette Devereux)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 671534225 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Date: May 27, 2005

Signature:

(Annette Devereux)

Docket No.: AO-CLFR:194USD1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Wylie Vale et al.

Application No.: 10/696,717

Confirmation No.:

Filed: October 29, 2003

Art Unit: N/A

For: BETAGLYCAN AS AN INHIBIN
RECEPTOR AND USES THEREOF

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each reference on the PTO/SB/08 is attached.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. AO-CLFR:194USD1. A duplicate copy of this paper is enclosed.

Dated: May 27, 2005

Respectfully submitted,

By 

Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.


Fulbright Tower

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/696,717
				Filing Date	October 29, 2003
				First Named Inventor	Wylie Vale
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	AO-CLFR:194USD1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-4,864,019	09/1989	Vale et al.	
	AB	US-5,102,868	04/1992	Woodruff et al.	
	AC	US-5,428,011	06/1995	Sheth et al.	
	AD	US-5,786,179	07/1998	Kousoulas et al.	
	AE	US-5,830,671	11/1998	Dennis et al.	
	AF	US-6,060,460	05/2000	Ferguson	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-9510610	04-20-1995	Jolla Cancer Res Foundation		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	CA	Brown et al., Science, March 1999, Vol. 283, pgs 2080-2082.		
	CB	Alberts et al, Molecular Biology if the Cell, 2nd Edition, 1989, pg 552.		
	CC	Lewis, K. et al, "Betaglycan Binds Inhibin and Can Mediate Functional Anatagonism of Activin Signalling," Nature Vol. 404, 2000, pgs 411-414.		
	CD	Chong et al, "Immunocytochemical Localization of Latent Transforming Growth Factor-β1 Activation by Stimulated Macrophages," Journal of Cellular Physiology Vol. 178, 1999, pgs 275 - 283.		
	CE	DePaolo et al, "Inhibins, Activins, and Follistatins: The Saga Continues," P.S.E.B.M. Vol. 214, 1997, pgs 328 - 339.		
	CF	Chong et al, "Structure and Expression of a Membrane Component of the Inhibin Receptor System," Endocrinology Vol. 141, 2000, pgs 2600 - 2607.		
	CG	Kaname et al, "Betaglycan has Multiple Binding Sites for transforming Growth Factor-β1," Biochemical Journal Vol. 315, 1996, pgs 815 - 820.		
	CH	Draper et al, "Identification of an Inhibin Receptor in Gonadal Tumors from inhibit α-Subunit knockout Mice," The Journal of Biological Chemistry Vol. 273, 1998, pgs 398 - 403.		
	CI	Massague, J., "TGF-Beta Signal Transduction," Annu Rev Biochem Vol. 67, 1998, pgs 753 - 791.		
	CJ	Massague et al, "Cellular Receptors for Type Beta Transforming Growth Factor, J. Biol Chem Vol. 260, 1985, pgs 2636 - 2645.		
	CK	Lopez-Casillas et al, "Structure and Expression of the Membrane Proteoglycan Betaglycan, a Component of teh TGF-beta Receptor System," Cell Vol. 67, 1991, pgs 785 - 795.		
	CL	Wang et al, "Expression Cloning and Characterization of the TGF-beta Type III Receptor," Cell Vol. 67, pgs 797-805.		

Examiner Signature	Date Considered
--------------------	-----------------



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


<div>Substitute for form 1449A/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>				Complete if Known	
				Application Number	10/696,717
				Filing Date	October 29, 2003
				First Named Inventor	Wylie Vale
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	AO-CLFR:194USD1
Sheet	2	of	2		

	CM	Derynck et al, "TGF-Beta Receptor Signaling," Biochim Biophys Acta Vol. 1333, pgs F105 - 50.	
	CN	Lopez-Casillas et al, "Betaglycan can Act as a Dual Modulator of TGF-Beta Access to Signaling Receptors: Mapping of Ligand Binding and GAG Attachment Sites," J Cell Biol Vol. 124, pgs. 557-568.	
	CO	Sun et al, "Expression of Transforming Growth Factor Beta Type III receptor Suppresses Tumorigenicity of Human Breast Cancer MDA-MB-231 Cells," J. Biol Chem Vol. 272, 1997, pgs 25367 - 25372.	
	CP	Chen et al, "Expression of Transforming Growth Factor Beta (TGFbeta) type III Receptor Restores Autocrine TGFbeta1 Activity in Human Breast Cancer MCF-7 Cells," J Biol Chem Vol. 272, 1997, pgs 12862 - 12867.	
	CQ	Brown et al, "Requirement of Type III TGF-Beta Receptor for Endocardial Cell Transformation in the Heart," Science Vol. 283, pgs 2080-2082.	
	CR	LeBrun et al, "Activin and Inhibin have Antagonistic Effects on Ligand-Dependant Heteromerization of the Type I and Type II Activin Receptors and Human Erythroid Differentiation," Molecular and Cellular Biology Vol. 17, no. 3, March 1997, pgs 1682 - 1691.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



Application No. (If known): 10/696,717

Attorney Docket No.: AO-CLFR:194USD1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV 671534225 US in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on May 27, 2005
Date

Signature

Annette Devereux

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (2 pages)
Information Disclosure Statement
Transmittal